Results 51 to 60 of about 49,423 (253)

Alopecia areata – Current understanding and management [PDF]

, 2022
Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute or chronic non-scarring hair loss, with a heterogeneity in clinical manifestations ranging from patchy hair loss to complete scalp and body hair loss. An overview of the up-
Blume‐Peytavi, Ulrike, Constantinou, Andria, Ghoreschi, Kamran, Hillmann, Kathrin, Lintzeri, Dimitra Aikaterini, Vogt, Annika   +5 more
core   +1 more source

Scalp micro-needling: A new tool in the treatment of alopecia totalis

Clinical Dermatology Review, 2020
Alopecia areata is the most common form of nonscarring alopecia. It may vary from a single round patch to that involving large surface area termed as alopecia totalis (AT).
Savitha L Beergouder, Apoorva Reshme
doaj   +1 more source

Attenuation of Autoimmune Phenomena in a Patient with Autoimmune Polyglandular Syndrome Type 1

Case Reports in Endocrinology, 2021
Autoimmune polyglandular syndrome type 1 (APS1) is a progressive life-threatening illness with no known cure. Current treatments involve replacement of the hormone deficiencies that result from autoimmune destruction of multiple endocrine organs.
Jill D. Jacobson, Julia R. Broussard, Courtney Marsh, Brandon Newell   +3 more
doaj   +1 more source

Alopecia areata: a multifactorial autoimmune condition [PDF]

, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P., Henriquez, Fiona L., Reid, Stuart, Simakou, Teontor   +3 more
core   +1 more source

Comorbidities, Healthcare Utilization, and Costs Associated With Alopecia Totalis and Alopecia Universalis in the United States

SKIN The Journal of Cutaneous Medicine, 2022
Background: Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Extensive forms of AA include alopecia totalis (AT; complete scalp hair loss) or alopecia universalis (AU; complete scalp, face, and body hair loss ...
Carolyn Maskin, A. Mostaghimi, Aster Meche, M. Ray, Kavita Gandhi, D. Gruben, V. Sikirica   +6 more
semanticscholar   +1 more source

Platelet-rich plasma efficacy in alopecia areata patients with normal and elevated levels of antibodies against thyroglobulin and thyroid peroxidase [PDF]

Folia Medica
Aim: To evaluate and compare the efficacy of platelet-rich plasma (PRP) therapy in alopecia areata (AA) patients with normal and with elevated levels of anti-thyroglobulin antibodies and/or anti-thyroid peroxidase antibodies.
Tsvetana I. Abadjieva, Lidiya N. Todorova, Petya A. Gardjeva, Mariana A. Murdjeva   +3 more
doaj   +3 more sources

Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis

JAMA dermatology, 2023
Importance Poor therapeutic results have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the most severe and disabling types of alopecia areata (AA). Methotrexate, an inexpensive treatment, might be effective in AU and AT.
P. Joly, Audrey Lafon, Estelle Houivet, Nathalie Donnadieu, M.‐A. Richard, A. Dupuy, Éric Delaporte, Philippe Bernard, L. Machet, Antonellá Tosti, V. del Mármol, Ramón Grimalt, Pierre A. de Viragh, Jacques Bénichou, O. Chosidow, P. Assouly, Pascal Reygagne   +16 more
openalex   +3 more sources

Alopecia Areata: Treatment of Today and Tomorrow [PDF]

, 2003
It is the aim of this article to review and appraise available data on treatments for alopecia areata (AA) according to the demands of evidence based medicine. Studies evaluating the efficacy of a treatment for AA should include appropriate controls, use
Freyschmidt-Paul, Pia, Happle, Rudolf, Hoffmann, Rolf, McElwee, Kevin J.   +3 more
core   +1 more source

Retrospective review of diphencyprone in the treatment of alopecia areata [PDF]

, 2015
Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.
Holmes, S., Lamb, R. C., Young, D.
core   +1 more source

Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecial Totalis and Alopecia Universalis: A Randomized, Double-Blind, Placebo-Controlled Trial

Siriraj Medical Journal, 2017
Background: Alopecia totalis (AT) and alopecia universalis (AU) have a high rate of recurrence and are very difficult to treat. To date, no consensus has been reach among clinicians regarding the best way to treat these conditions.
Rattapon Thuangtong
doaj   +3 more sources